Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis
Yiqing Li, … , Xue Zhang, Yuehai Ke
Yiqing Li, … , Xue Zhang, Yuehai Ke
Published January 10, 2023
Citation Information: J Clin Invest. 2023;133(4):e162870. https://doi.org/10.1172/JCI162870.
View: Text | PDF
Research Article Cell biology

SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis

  • Text
  • PDF
Abstract

SIPRα on macrophages binds with CD47 to resist proengulfment signals, but how the downstream signal of SIPRα controls tumor-infiltrating macrophages (TIMs) is still poorly clarified. Here, we report that the CD47/signal regulatory protein α (SIRPα) axis requires the deneddylation of tyrosine phosphatase SHP2. Mechanistically, Src homology region 2–containing protein tyrosine phosphatase 2 (SHP2) was constitutively neddylated on K358 and K364 sites; thus, its autoinhibited conformation was maintained. In response to CD47-liganded SIRPα, SHP2 was deneddylated by sentrin-specific protease 8 (SENP8), which led to the dephosphorylation of relevant substrates at the phagocytic cup and subsequent inhibition of macrophage phagocytosis. Furthermore, neddylation inactivated myeloid-SHP2 and greatly boosted the efficacy of colorectal cancer (CRC) immunotherapy. Importantly, we observed that supplementation with SHP2 allosteric inhibitors sensitized immune treatment–resistant CRC to immunotherapy. Our results emphasize that the CRC subtype that is unresponsive to immunotherapy relies on SIRPαhiSHP2hiNEDD8lo TIMs and highlight the need to further explore the strategy of SHP2 targeting in CRC therapy.

Authors

Yiqing Li, Hui Zhou, Pan Liu, Dandan Lv, Yichun Shi, Bufu Tang, Jiaqi Xu, Tingting Zhong, Wangting Xu, Jie Zhang, Jianying Zhou, Kejing Ying, Yongchao Zhao, Yi Sun, Zhinong Jiang, Hongqiang Cheng, Xue Zhang, Yuehai Ke

×

Figure 1

Neddylation and SENP8 play a regulatory role in response to CD47 stimulation.

Options: View larger image (or click on image) Download as PowerPoint
Neddylation and SENP8 play a regulatory role in response to CD47 stimula...
(A) Violin plot of SIRPA gene expression levels in different TIMs. (B) Violin plot of NEDD8 gene expression levels in SIRPα+ TIMs. (C) TSNE plots of NEDD8 gene expression levels in tumor-infiltrating myeloid cells. ESCA, esophageal carcinoma; KIDNEY, kidney cancer; LYM, lymphoma; MYE, myeloma; OV-FTC, ovarian or fallopian tube carcinoma; PAAD, pancreatic adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma. (D) TSNE plot shows lineages of tumor-infiltrating leukocytes in control (left) and CD47/SIRPα–blocking peptide–treated (Pep-20, 2 mg/kg, right) MC38 s.c. tumors (n = 6). mc numbers refer to major varied mouse clusters. (E) TSNE visualization of CD206 and SIRPα expression groups shown in D. (F) NEDD8 expression in total tumor-infiltrating monocytes/macrophages of groups show in D. (G) iNOS expression of major varied mouse clusters of Pep-20–treated groups. (H) TSNE visualization of NEDD8, SENP8, and Ki-67 expression in Pep-20–treated groups; mc16 and mc17 are circled.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts